Institute of Cancer Research: As part of the ARTISTIC trial, between 2001-09, 24510 women underwent HPV testing with genotyping.

Data-sharing agreement from NHS Digital registers of approved data releases, 2014–2019. Evidence status: source reported.

Organisation

Institute of Cancer Research

Source reference

DARS-NIC-226323-X4L5B-v0.0

Jurisdiction

England

Licence

Open Government Licence v3.0, subject to NHS England terms and exclusions

As part of the ARTISTIC trial, between 2001-09, 24510 women underwent HPV testing with genotyping. This project concerns long-term follow-up of this unique cohort through notification of cancer and death. The aim is to evaluate the long-term value of HPV testing as a primary screening strategy. Cervical screening intervals of 6-10 years following a negative HPV test are now being considered and which demonstrates the importance of long-term data on cohorts such as ARTISTIC. The universal introduction of primary HPV testing in the NHS cervical screening programme will require several practical

Register reference

DARS-NIC-226323-X4L5B-v0.0

Agreement period

not published to no end date published

For commercial purposes (as marked in the register)

Not stated

Release files listed by NHS England

2

Data approved

• MRIS - Cause of Death Report
• MRIS - Cohort Event Notification Report

Objective, as published

As part of the ARTISTIC trial, between 2001-09, 24510 women underwent HPV testing with genotyping. This project concerns long-term follow-up of this unique cohort through notification of cancer and death. The aim is to evaluate the long-term value of HPV testing as a primary screening strategy. Cervical screening intervals of 6-10 years following a negative HPV test are now being considered and which demonstrates the importance of long-term data on cohorts such as ARTISTIC. The universal introduction of primary HPV testing in the NHS cervical screening programme will require several practical decisions on test method and frequency with large effects on costs, staff time and patient acceptability, as well as on effectiveness of cancer prevention. Our findings will add to the body of evidence to allow policy -makers to improve the cervical screening programme in the UK (and around the world). The results will be presented at international HPV conferences and published in peer-reviewed journals. In addition, anonymised individual data (including events notified through this flagging process) has been pooled with 3 other European trials in order to evaluate the efficacy of HPV testing for preventing invasive cervical cancer (to be published in the Lancet shortly). In screened cohorts, invasive cervical cancer is so rare that pooling data with other large studies is the best way to evaluate this.

Source: https://webarchive.nationalarchives.gov.uk/ukgwa/2019/http://content.digital.nhs.uk/media/22305/Data-Release-Register-April-to-August-2016/xls/Data_Release_Register__April_-_August_2016.xlsx. Captured 2026-10-30.

Limitations: Agreement as recorded in an NHS Digital register of approved data releases (2014–2019), retrieved from the UK Government Web Archive. That register lists releases made in its period and the agreement's purpose statement as it then stood; it gives no agreement dates, and the agreement may have changed since. Imported only where a paper quotes a reference no current register holds.